Cancer News and Research

Latest Cancer News and Research

New molecular imaging technique raises hope for common malignant female tumor

A promising new molecular imaging technique may provide physicians and patients with a noninvasive way to learn more information about a type of cancer of the uterus lining called "endometrial carcinoma"-one of the most common malignant female tumors. This research was presented in a study published in the October issue of The Journal of Nuclear Medicine.

1 Oct 2009

Screening and diagnostic tests contribute to health care value across spectrum of care

Amidst ongoing debate in Congress over reforming the nation's health care system, a new report from the Lewin Group finds that screening and diagnostic laboratory tests are central to achieving some of the most important goals of health care reform.

1 Oct 2009

Fast track assessment facilities can contribute to timely evaluation of lung malignancies

Research published in the October 2009 issue of the Journal of Thoracic Oncology has found an effective combination of positron emission tomography (PET)/computed tomography (CT) (PET/CT) tests to diagnose lung cancer in a "fast-tracked" outpatient setting. This novel approach to the diagnosis of lung cancer demonstrated a high level of sensitivity (97%) and accuracy (82%).

1 Oct 2009

Doris Duke Innovations award for sickle cell disease research

Sangamo BioSciences, Inc. announced today that research led by Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics (MIMG) and Pediatrics, the Director of the UCLA Human Gene Medicine Program and member of the Broad Stem Cell Research Center, and Philip Gregory, D. Phil., Sangamo's chief scientific officer and vice president, research, has been selected to receive a $486,000 Doris Duke Innovations in Clinical Research Award from the Doris Duke Charitable Foundation.

1 Oct 2009

Merrimack and sanofi-aventis collaborate to develop and co-commercialize MM-121, a monoclonal antibody

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today the signing of an exclusive worldwide licensing agreement for the development and co-commercialization of MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 receptor. MM-121 is currently in Phase 1 clinical testing.

1 Oct 2009

ASCRO adds non-profit organization to the radiation oncology field

The founding members of the American Society of Clinical Radiation Oncology, ASCRO, are very pleased to announce the addition of this professional non-profit organization to the radiation oncology field. ASCRO is primarily dedicated to acquiring a "Provider Status" for clinical radiation oncology physicists.

1 Oct 2009

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company’s lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.

1 Oct 2009

Public lecture to highlight what causes cell division to go wrong and lead to cancer

University of Leicester research which substantially increases our understanding of what causes cell division to go wrong and lead to cancer will be highlighted in a public lecture at the University on Wednesday 14th October at 5.30-6.30pm.

1 Oct 2009

Cutting Edge Information hopes to see ill patients have speedier access to potential cures

The FDA has approved the first set of vaccines aimed at preventing H1N1 infection after an approval process of less than four months. Cutting Edge Information is currently analyzing the lessons learned that may emerge for both the Food and Drug Administration (FDA) and life science firms after this crisis experience.

1 Oct 2009

TMS closes final tranche of Series E Preferred Financing to a total of $6 million

TechniScan Medical Systems (TMS) Inc., a Salt Lake City-based developer of ultrasound technology for breast imaging, announced the close of the final tranche of their Series E Preferred Financing of $1.1 million, bringing the total raised in the Series E financing to just over $6 million.

1 Oct 2009

Raptor Pharmaceutical appoints Llew Keltner to its board of directors

Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), today announced the appointment of Llew Keltner, M.D., Ph.D., to the Company's board of directors. Dr. Keltner is currently CEO and President of Light Sciences Oncology, a privately-held biotechnology company developing a late-stage, light-activated therapy for hepatocellular cancer and other solid tumors.

1 Oct 2009

Cord Blood America to open cryogenic research and storage laboratory in Las Vegas

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that it is opening its new Corporate headquarters and cryogenic research and storage laboratory in Las Vegas, as planned, the first week of October.

1 Oct 2009

Invivo Corporation introduces advanced clinical prostate visualization system

The introduction of Invivo Corporation's DynaCAD for Prostate advanced clinical visualization and MR interventional system brings new hope to patients and new confidence to their care providers, a positive development this Prostate Cancer Awareness Month.

1 Oct 2009

Intoxicated trauma patients have higher survial rates than sober patients: Study

Trauma patients who were intoxicated before their injuries were more likely to survive than trauma patients who suffered similar injuries but were sober at the time, according to a study published in the October edition of the American Surgeon that was conducted by researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed).

1 Oct 2009

Novartis Oncology, Amgen, GlaxoSmithKline and Veridex honored with 2009 Prix Galien Award

The Prix Galien USA committee celebrated members of the science and biotechnology industries last night for the development and discovery of drugs and technologies that improve the human condition.

1 Oct 2009

Retailers join to support breast cancer research

This October, retailers nationwide are joining the fight against breast cancer by offering pink ribbon products that benefit research, treatment and education programs at City of Hope, one of the nation’s leading cancer research and treatment centers. From skin and hair care treatments to apparel to office products, consumers can feel good about their purchases and help support lifesaving cancer research.

1 Oct 2009

Membrane-bound Fas ligand is essential for cell death: Researchers

Walter and Eliza Hall Institute researchers have put an end to a 10-year debate over which form of a molecular messenger called Fas ligand is responsible for killing cells during programmed cell death (also called apoptosis).

1 Oct 2009

Society of Interventional Radiology offers intensive five-day course

The Society of Interventional Radiology presents Catheter Lysis of Thromboembolic Stroke (CLOTS)-an intensive five-day course featuring top interventional radiologists, neurointerventionists, neurologists and neuroradiologists offering doctors the opportunity to gain and/or upgrade skills to incorporate acute ischemic stroke care into their practice.

1 Oct 2009

People with a gun more likely to be shot in an assault than those without one

In a first-of its-kind study, epidemiologists at the University of Pennsylvania School of Medicine found that, on average, guns did not protect those who possessed them from being shot in an assault. The study estimated that people with a gun were 4.5 times more likely to be shot in an assault than those not possessing a gun.

1 Oct 2009

Promising results from Cell Therapeutics' phase II OPAXIO study for advanced esophageal cancer

Cell Therapeutics, Inc. announced today that, in a study from Brown University to be presented by Howard Safran, M.D., head of the Brown University Oncology Group, in the proffered oral session at the Annual Meeting of the International Society of Gastrointestinal Oncology (ISGIO) in Philadelphia, Pennsylvania patients with cancer of the lower esophagus demonstrated a high rate of complete remission (CR) when given OPAXIO(TM) (paclitaxel poliglumex), a biologically enhanced paclitaxel, when administered in combination with standard cisplatin and concurrent radiation.

1 Oct 2009

Cancer News and Research

Latest Cancer News and Research

New molecular imaging technique raises hope for common malignant female tumor

Screening and diagnostic tests contribute to health care value across spectrum of care

Fast track assessment facilities can contribute to timely evaluation of lung malignancies

Doris Duke Innovations award for sickle cell disease research

Merrimack and sanofi-aventis collaborate to develop and co-commercialize MM-121, a monoclonal antibody

ASCRO adds non-profit organization to the radiation oncology field

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Public lecture to highlight what causes cell division to go wrong and lead to cancer

Cutting Edge Information hopes to see ill patients have speedier access to potential cures

TMS closes final tranche of Series E Preferred Financing to a total of $6 million

Raptor Pharmaceutical appoints Llew Keltner to its board of directors

Cord Blood America to open cryogenic research and storage laboratory in Las Vegas

Invivo Corporation introduces advanced clinical prostate visualization system

Intoxicated trauma patients have higher survial rates than sober patients: Study

Novartis Oncology, Amgen, GlaxoSmithKline and Veridex honored with 2009 Prix Galien Award

Retailers join to support breast cancer research

Membrane-bound Fas ligand is essential for cell death: Researchers

Society of Interventional Radiology offers intensive five-day course

People with a gun more likely to be shot in an assault than those without one

Promising results from Cell Therapeutics' phase II OPAXIO study for advanced esophageal cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in